

*STN Scan*

FILE 'HOME' ENTERED AT 15:28:37 ON 09 DEC 2003

L1 18623 INFLUENZA (S) VIRUS (P) (VACCINE OR IMMUNOGEN##### OR ANTIGEN)  
L2 21867 INFLUENZA (P) (VACCINE OR IMMUNOGEN##### OR ANTIGEN) AND INFLUENZA (S) VIRUS  
L3 97 L2 AND (HEAT (S) INACTIVAT##### OR HEAT-INACTIVAT#####) (S) (VIRUS OR IMMUNOGEN OR INFLUENZA)  
L6 648 L2 AND (ORAL## OR PILL OR TABLET OR CAPSULE) (P) (VACCINE OR VIRUS OR COMPOSTION OR FORMULAT#####)

(FILE 'HOME' ENTERED AT 15:28:37 ON 09 DEC 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 15:30:07 ON 09 DEC 2003

L1 18623 S INFLUENZA (S) VIRUS (P) (VACCINE OR IMMUNOGEN##### OR ANTIGEN)  
L2 21867 S INFLUENZA (P) (VACCINE OR IMMUNOGEN##### OR ANTIGEN) AND INFL  
L3 97 S L2 AND (HEAT (S) INACTIVAT##### OR HEAT-INACTIVAT#####) (S) (44 DUP REM L3 (53 DUPLICATES REMOVED))  
L4 30 S L4 NOT PY>2000  
L5 648 S L2 AND (ORAL## OR PILL OR TABLET OR CAPSULE) (P) (VACCINE OR  
L6 10 S L6 AND L3  
L7 28 S L5 NOT L7

L7 ANSWER 1 OF 10 MEDLINE on STN  
AN 97347317 MEDLINE  
DN 97347317 PubMed ID: 9203656  
TI Adjuvant activity of the **heat-labile** enterotoxin from enterotoxigenic Escherichia coli for **oral** administration of **inactivated influenza virus vaccine**.  
AU Katz J M; Lu X; Young S A; Galphin J C  
CS Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.  
SO JOURNAL OF INFECTIOUS DISEASES, (1997 Feb) 175 (2) 352-63.  
Journal code: 0413675. ISSN: 0022-1899.  
CY United States  
DT (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 199707  
ED Entered STN: 19970724  
Last Updated on STN: 19970724  
Entered Medline: 19970716  
AB Alternative strategies for vaccination against **influenza** that elicit both systemic antibody and mucosal IgA responses are needed to improve the efficacy in protection against infection. This study demonstrated that **oral** delivery of **inactivated influenza vaccine** with the **heat-labile** enterotoxin (LT) from enterotoxigenic Escherichia coli elicited the spectrum of humoral and cell-mediated responses in BALB/c mice critical for the protection and recovery from **influenza virus** infection. Coadministration of LT with **oral influenza vaccine** increased antiviral serum IgG and mucosal IgA responses compared with administration of **oral influenza vaccine** alone. Serum hemagglutination-inhibition and neutralizing antibodies were also augmented by LT. The adjuvant potentiated protection from infection with **influenza A H3N2 viruses** in mouse lower and upper respiratory tracts, enabling the use of lower doses of **oral vaccine**. Coadministration of LT with **oral inactivated influenza vaccine** induced **influenza virus**-specific proliferative T cells, interleukin-2 production, and major histocompatibility complex class I-restricted cytotoxic T cells.

L7 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 2002:66290 CAPLUS  
DN 137:167825  
TI Mutant Escherichia coli **heat-labile** enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered **inactivated influenza vaccine**  
AU Lu, Xiuhua; Clements, J. D.; Katz, Jacqueline M.  
CS Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, 30333, USA  
SO Vaccine (2002), 20(7-8), 1019-1029  
CODEN: VACCDE; ISSN: 0264-410X  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
AB **Influenza vaccines** capable of inducing both systemic and mucosal antibody responses are highly desirable. Optimal induction of

mucosal IgA is accomplished by mucosal delivery of **vaccine**. Mucosal adjuvants may improve the **immunogenicity** and efficacy of **vaccines** delivered by this route. Here, we compare the adjuvant activities of a mutant of **heat-labile enterotoxin** from *Escherichia coli* [LT(R192G)] with those of the wildtype LT (wtLT) for oral vaccination with **inactivated influenza vaccine** in BALB/c mice. Compared with administration of oral **influenza vaccine** alone, co-administration of **vaccine** with LT(R192G) provided enhanced protection from infection in the upper and lower respiratory tract equiv. to and at similar doses as that obtained with wtLT. Likewise, LT(R192G) augmented **virus**-specific IgG and IgA responses in serum, lung and nasal washes and the nos. of **virus**-specific antibody-forming cells in spleen, lung and Peyer's patches in a manner comparable to wtLT. **Virus**-specific splenic CD4+ cells from mice administered oral **vaccine** with either adjuvant produced a mixed Th1- and Th2-type cytokine response pattern. Taken together, these results indicate that LT(R192G), like wtLT, is a potent adjuvant for oral vaccination of mice with **influenza vaccine**.

RE.CNT 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 1997:125169 CAPLUS  
DN 126:180877  
TI Adjuvant activity of the **heat-labile enterotoxin** from enterotoxigenic *Escherichia coli* for **oral** administration of **inactivated influenza virus vaccine**  
AU Katz, Jacqueline M.; Lu, XiuHua; Young, Sarah A.; Galphin, Judith C.  
CS Influenza Branch, Natl. Cent. Infectious Diseases, Atlanta, GA, USA  
SO Journal of Infectious Diseases (1997), 175(2), 352-363  
CODEN: JIDIAQ; ISSN: 0022-1899  
PB University of Chicago Press  
DT Journal  
LA English  
AB Alternative strategies for vaccination against **influenza** that elicit both systemic antibody and mucosal IgA responses are need to improve the efficacy in protection against infection. This study demonstrated that **oral** delivery of **inactivated influenza vaccine** with the **heat-labile enterotoxin** (LT) from enterotoxigenic *Escherichia coli* elicited the spectrum of humoral and cell-mediated responses in BALB/c mice crit. for the protection and recovery from **influenza virus** infection. Coadministration of LT with **oral influenza vaccine** increased antiviral serum IgG and mucosal IgA responses compared with administration of **oral influenza vaccine** alone. Serum hemagglutination-inhibition and neutralizing antibodies were also augmented by LT. The adjuvant potentiated protection from infection with **influenza A H3N2 viruses** in mouse lower and upper respiratory tracts, enabling the use of lower doses of **oral vaccine**. Coadministration of LT with **oral inactivated influenza vaccine** induced **influenza virus**-specific proliferative T cells, interleukin-2 prodn., and major histocompatibility complex class-I-restricted cytotoxic T cells.

L7 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 1985:452369 CAPLUS  
DN 103:52369  
TI Use of gamma-inactivated **vaccines** for immunization against **influenza** in animal experiments

AU Bergmann, K. C.; Noack, K.; Tischner, H.; Pohl, W. D.; Nordheim, W.; Braeuniger, S.; Petzold, G.; Ngyen, H.  
CS Res. Inst. Lung Dis. Tuberc., Berlin, Ger. Dem. Rep.  
SO ZFI-Mitteilungen (1984), 98, 673-8  
CODEN: ZIMIDC; ISSN: 0323-8776  
DT Journal  
LA English  
AB 60Co-.gamma.-**inactivated influenza** (A/PR/8/34)  
**vaccines** were compared with live and conventionally **heat**-  
**inactivated vaccines** administered by the **oral**  
or parenteral route to NMRI-mice. As compared to the parenteral group,  
**oral** immunization with inactivated **vaccines** leads to  
higher secretory antibody response in the lung. The antibody response  
correlates with protection against lethal **virus** challenge by  
aerosol characterized by a low cell yield and **virus** titer in the  
lung and high survival rate. In monkeys (macacus rhesus) the **oral**  
uptake of a .gamma.-**inactivated influenza vaccine**  
leads also to the occurrence of specific antibodies in nasal secretions  
and saliva and was well tolerated. Thus, inactivation by irradn. can be  
used for easy and probably inexpensive prodn. of **oral**  
**influenza vaccines**.

L7 ANSWER 5 OF 10 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
AN 2002:343979 BIOSIS  
DN PREV200200343979  
TI Effect of pre-existing anti-LT (heat-labile enterotoxin of Escherichia  
coli) immunity on the efficacy of **oral influenza**  
**vaccine**.  
AU Lu, Xiuhua [Reprint author]; Katz, Jacqueline M. [Reprint author]  
CS Influenza Branch, CDC, 1600 Clifton Rd, Atlanta, GA, 30333, USA  
SO FASEB Journal, (March 20, 2002) Vol. 16, No. 4, pp. A680. print.  
Meeting Info.: Annual Meeting of the Professional Research Scientists on  
Experimental Biology. New Orleans, Louisiana, USA. April 20-24, 2002.  
CODEN: FAJOEC. ISSN: 0892-6638.  
DT Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LA English  
ED Entered STN: 19 Jun 2002  
Last Updated on STN: 19 Jun 2002  
AB Previously, we have shown that **heat**-labile enterotoxin (LT) from  
E. coli and its low-toxicity mutant (LTR192G) are powerful adjuvants for  
the mucosal delivery of **inactivated influenza**  
**vaccine** to BALB/c mice. However, these adjuvants are also potent  
mucosal **immunogens**. Thus for **vaccines** such as the  
**influenza vaccine**, which may be administered annually to  
individuals, a key question is whether pre-existing immunity to LT would  
result in reduced adjuvant activity and hence, **vaccine** efficacy.  
To address this question, we compared the levels of **virus**  
-specific antibody production, cytokine production, and protective  
efficacy induced by **oral influenza vaccine**  
administered with LT adjuvant to mice that were or were not previously  
immunized with LT. We demonstrated that while preexisting immunity to LT  
reduced the subsequent serum and local **influenza virus**  
-specific antibody responses and cytokine production, the protective  
effect of the **influenza vaccine** was not impaired.  
Further evaluation of the safety and adjuvant activity of low toxicity  
mutants of LT will determine the ultimate utility of such adjuvants in  
humans.

L7 ANSWER 6 OF 10 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
AN 1997:107155 BIOSIS

DN PREV199799406358  
TI Adjuvant activity of the **heat-labile** enterotoxin from enterotoxigenic Escherichia coli for **oral** administration of **inactivated influenza virus vaccine**.  
AU Katz, Jacqueline M. [Reprint author]; Lu, XiuHua; Young, Sarah A.; Galphin, Judith C.  
CS Influenza Branch, Mailstop G16, Div. Viral and Rickettsial Dis., Cent. Dis. Control Prev., 1600 Clifton Rd., Atlanta, GA 30333, USA  
SO Journal of Infectious Diseases, (1997) Vol. 175, No. 2, pp. 352-363.  
CODEN: JIDIAQ. ISSN: 0022-1899.  
DT Article  
LA English  
ED Entered STN: 10 Mar 1997  
Last Updated on STN: 10 Mar 1997  
AB Alternative strategies for vaccination against **influenza** that elicit both systemic antibody and mucosal IgA responses are needed to improve the efficacy in protection against infection. This study demonstrated that **oral** delivery of **inactivated influenza vaccine** with the **heat-labile** enterotoxin (LT) from enterotoxigenic Escherichia coli elicited the spectrum of humoral and cell-mediated responses in BALB/c mice critical for the protection and recovery from **influenza virus** infection. Coadministration of LT with **oral influenza vaccine** increased antiviral serum IgG and mucosal IgA responses compared with administration of **oral influenza vaccine** alone. Serum hemagglutination-inhibition and neutralizing antibodies were also augmented by LT. The adjuvant potentiated protection from infection with **influenza A H3N2 viruses** in mouse lower and upper respiratory tracts, enabling the use of lower doses of **oral vaccine**. Coadministration of LT with **oral inactivated influenza vaccine** induced **influenza virus**-specific proliferative T cells, interleukin-2 production, and major histocompatibility complex class I-restricted cytotoxic T cells.

L7 ANSWER 7 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN  
AN 2002060517 EMBASE  
TI Mutant Escherichia coli **heat-labile** enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to **orally** administered **inactivated influenza vaccine**.  
AU Lu X.; Clements J.D.; Katz J.M.  
CS J.M. Katz, Div. of Viral/Rickettsial Diseases, Natl. Center for Infectious Diseases, Ctr. for Disease Control/Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States. jkatz@cdc.gov  
SO Vaccine, (15 Jan 2002) 20/7-8 (1019-1029).  
Refs: 73  
ISSN: 0264-410X CODEN: VACCDE  
PUI S 0264-410X(01)00452-2  
CY United Kingdom  
DT Journal; Article  
FS 004 Microbiology  
026 Immunology, Serology and Transplantation  
037 Drug Literature Index  
LA English  
SL English  
AB **Influenza vaccines** capable of inducing both systemic and mucosal antibody responses are highly desirable. Optimal induction of mucosal IgA is accomplished by mucosal delivery of **vaccine**.

Mucosal adjuvants may improve the **immunogenicity** and efficacy of **vaccines** delivered by this route. Here, we compare the adjuvant activities of a mutant of **heat-labile enterotoxin** from *Escherichia coli* [LT(R192G)] with those of the wildtype LT (wtLT) for **oral vaccination with inactivated influenza vaccine** in BALB/c mice. Compared with administration of **oral influenza vaccine** alone, co-administration of **vaccine** with LT(R192G) provided enhanced protection from infection in the upper and lower respiratory tract equivalent to and at similar doses as that obtained with wtLT. Likewise, LT(R192G) augmented **virus**-specific IgG and IgA responses in serum, lung and nasal washes and the numbers of **virus**-specific antibody-forming cells in spleen, lung and Peyer's patches in a manner comparable to wtLT. **Virus**-specific splenic CD4(+) cells from mice administered **oral vaccine** with either adjuvant produced a mixed Th1- and Th2-type cytokine response pattern. Taken together, these results indicate that LT(R192G), like wtLT, is a potent adjuvant for **oral vaccination of mice with influenza vaccine**.

L7 ANSWER 8 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN  
AN 97036029 EMBASE  
DN 1997036029  
TI Adjuvant activity of the **heat-labile enterotoxin** from enterotoxigenic *Escherichia coli* for **oral** administration of **inactivated influenza virus vaccine**.  
AU Katz J.M.; Lu X.; Young S.A.; Galpin J.C.  
CS Dr. J.M. Katz, Influenza Branch, Div. of Viral/Rickettsial Diseases, Ctrs. for Disease Control/Prevention, 1600 Clifton Rd., Atlanta, GA 30333, United States  
SO Journal of Infectious Diseases, (1997) 175/2 (352-363).  
Refs: 42  
ISSN: 0022-1899 CODEN: JIDIAQ  
CY United States  
DT Journal; Article  
FS 004 Microbiology  
037 Drug Literature Index  
LA English  
SL English  
AB Alternative strategies for vaccination against **influenza** that elicit both systemic antibody and mucosal IgA responses are needed to improve the efficacy in protection against infection. This study demonstrated that **oral** delivery of **inactivated influenza vaccine** with the **heat-labile enterotoxin** (LT) from enterotoxigenic *Escherichia coli* elicited the spectrum of humoral and cell-mediated responses in BALB/c mice critical for the protection and recovery from **influenza virus** infection. Coadministration of LT with **oral influenza vaccine** increased antiviral serum IgG and mucosal IgA responses compared with administration of **oral influenza vaccine** alone. Serum hemagglutination-inhibition and neutralizing antibodies were also augmented by LT. The adjuvant potentiated protection from infection with **influenza A H3N2 viruses** in mouse lower and upper respiratory tracts, enabling the use of lower doses of **oral vaccine**. Coadministration of LT with **oral inactivated influenza vaccine** induced **influenza virus**-specific proliferative T cells, interleukin-2 production, and major histocompatibility complex class I-restricted cytotoxic T cells.

L7 ANSWER 9 OF 10 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN  
AN 2002:176290 SCISEARCH  
GA The Genuine Article (R) Number: 521TV  
TI Mutant Escherichia coli **heat-labile enterotoxin [LT(R192G)]**  
enhances protective humoral and cellular immune responses to  
**orally administered inactivated influenza**  
**vaccine**  
AU Lu X H; Clements J D; Katz J M (Reprint)  
CS CDCP, Natl Ctr Infect Dis, Div Viral & Rickettsial Dis, Influenza Branch,  
1600 Clifton Rd, Atlanta, GA 30333 USA (Reprint); CDCP, Natl Ctr Infect  
Dis, Div Viral & Rickettsial Dis, Influenza Branch, Atlanta, GA 30333 USA;  
Tulane Univ, Med Ctr, Dept Microbiol & Immunol, New Orleans, LA 70112 USA  
CYA USA  
SO VACCINE, (15 JAN 2002) Vol. 20, No. 7-8, pp. 1019-1029.  
Publisher: ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON,  
OXFORD OX5 1GB, OXON, ENGLAND.  
ISSN: 0264-410X.  
DT Article; Journal  
LA English  
REC Reference Count: 73  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*  
AB **Influenza vaccines** capable of inducing both  
systemic and mucosal antibody responses are highly desirable. Optimal  
induction of mucosal IgA is accomplished by mucosal delivery of  
**vaccine**, Mucosal adjuvants may improve the **immunogenicity**  
and efficacy of **vaccines** delivered by this route. Here, we  
compare the adjuvant activities of a mutant of **heat-labile**  
enterotoxin from *Escherichia coli* [LT(R192G)] with those of the wildtype  
LT (wtLT) for **oral** vaccination with **inactivated**  
**influenza vaccine** in BALB/c mice. Compared with  
administration of **oral influenza vaccine**  
alone, co-administration of **vaccine** with LT(R192G) provided  
enhanced protection from infection in the upper and lower respiratory  
tract equivalent to and at similar doses as that obtained with wtLT.  
Likewise, LT(R192G) augmented **virus**-specific I-G and I-A  
responses in serum, lung and nasal washes and the numbers of **virus**  
-specific antibody-forming cells in spleen, lung and Peyer's patches in a  
manner comparable to wtLT. **Virus**-specific splenic CD4(+) cells  
from mice administered **oral vaccine** with either  
adjuvant produced a mixed Th1 - and Th2-type cytokine response pattern.  
Taken together, these results indicate that LT(R192G), like wtLT, is a  
potent adjuvant for **oral** vaccination of mice with  
**influenza vaccine**. Published by Elsevier Science Ltd.

L7 ANSWER 10 OF 10 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN  
AN 97:118413 SCISEARCH  
GA The Genuine Article (R) Number: WF063  
TI Adjuvant activity of the **heat-labile enterotoxin** from  
enterotoxigenic *Escherichia coli* for **oral** administration of  
**inactivated influenza virus vaccine**  
AU Katz J M (Reprint); Lu X H; Young S A; Galphin J C  
CS CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL  
DIS, INFLUENZA BRANCH, ATLANTA, GA 30333 (Reprint); ST JUDE CHILDRENS  
HOSP, DEPT VIROL & MOL BIOL, MEMPHIS, TN 38105  
CYA USA  
SO JOURNAL OF INFECTIOUS DISEASES, (FEB 1997) Vol. 175, No. 2, pp. 352-363.  
Publisher: UNIV CHICAGO PRESS, 5720 S WOODLAWN AVE, CHICAGO, IL 60637.  
ISSN: 0022-1899.  
DT Article; Journal  
FS LIFE; CLIN  
LA English

REC Reference Count: 42  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB Alternative strategies for vaccination against **influenza** that elicit both systemic antibody and mucosal IgA responses are needed to improve the efficacy in protection against infection. This study demonstrated that **oral** delivery of **inactivated influenza vaccine** with the **heat-labile enterotoxin (LT)** from enterotoxigenic Escherichia coli elicited the spectrum of humoral and cell-mediated responses in BALB/c mice critical for the protection and recovery from **influenza virus** infection. Coadministration of LT with **oral influenza vaccine** increased antiviral serum IgG and mucosal IgA responses compared with administration of **oral influenza vaccine** alone. Serum hemagglutination-inhibition and neutralizing antibodies were also augmented by LT. The adjuvant potentiated protection from infection with **influenza A H3N2 viruses** in mouse lower and upper respiratory tracts, enabling the use of lower doses of **oral vaccine**. Coadministration of LT with **oral inactivated influenza vaccine** induced **influenza virus**-specific proliferative T cells, interleukin-2 production, and major histocompatibility complex class I-restricted cytotoxic T cells.

L8 ANSWER 1 OF 28 MEDLINE on STN  
ACCESSION NUMBER: 2000507325 MEDLINE  
DOCUMENT NUMBER: 20507670 PubMed ID: 11053627  
TITLE: Comparison of in vitro immunostimulatory potential of live  
and inactivated **influenza viruses**.  
AUTHOR: Blazevic V; Trubey C M; Shearer G M  
CORPORATE SOURCE: Experimental Immunology Branch, National Cancer Institute,  
National Institutes of Health, Bethesda, Maryland 20892,  
USA.  
CONTRACT NUMBER: N01-CO-56000 (NCI)  
SOURCE: HUMAN IMMUNOLOGY, (2000 Sep) 61 (9) 845-9.  
Journal code: 8010936. ISSN: 0198-8859.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200011  
ENTRY DATE: Entered STN: 20010322  
Last Updated on STN: 20010322  
Entered Medline: 20001128

L8 ANSWER 2 OF 28 MEDLINE on STN  
ACCESSION NUMBER: 1999346227 MEDLINE  
DOCUMENT NUMBER: 99346227 PubMed ID: 10417205  
TITLE: Intranasal immunization of mice with **influenza**  
**vaccine** in combination with the adjuvant LT-R72  
induces potent mucosal and serum immunity which is stronger  
than that with traditional intramuscular immunization.  
AUTHOR: Barackman J D; Ott G; O'Hagan D T  
CORPORATE SOURCE: Chiron Corporation, Emeryville, California, USA..  
john.barackman@cc.chiron.com  
SOURCE: INFECTION AND IMMUNITY, (1999 Aug) 67 (8) 4276-9.  
Journal code: 0246127. ISSN: 0019-9567.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199908  
ENTRY DATE: Entered STN: 19990820  
Last Updated on STN: 19990820  
Entered Medline: 19990812

L8 ANSWER 3 OF 28 MEDLINE on STN  
ACCESSION NUMBER: 96096440 MEDLINE  
DOCUMENT NUMBER: 96096440 PubMed ID: 7500011  
TITLE: Inactivated **influenza virus**, when  
presented on dendritic cells, elicits human CD8+ cytolytic  
T cell responses.  
AUTHOR: Bender A; Bui L K; Feldman M A; Larsson M; Bhardwaj N  
CORPORATE SOURCE: Rockefeller University, Laboratory of Cellular Physiology  
and Immunology, New York 10021, USA.  
CONTRACT NUMBER: AR-39552 (NIAMS)  
AR-42557 (NIAMS)  
SOURCE: JOURNAL OF EXPERIMENTAL MEDICINE, (1995 Dec 1) 182 (6)  
1663-71.  
Journal code: 2985109R. ISSN: 0022-1007.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals; AIDS

ENTRY MONTH: 199601  
ENTRY DATE: Entered STN: 19960217  
Last Updated on STN: 19960217  
Entered Medline: 19960117

L8 ANSWER 4 OF 28 MEDLINE on STN  
ACCESSION NUMBER: 95091056 MEDLINE  
DOCUMENT NUMBER: 95091056 PubMed ID: 7998417  
TITLE: Escherichia coli heat-labile enterotoxin B subunits  
supplemented with a trace amount of the holotoxin as an  
adjuvant for nasal **influenza vaccine**.  
AUTHOR: Tamura S; Asanuma H; Tomita T; Komase K; Kawahara K;  
Danbara H; Hattori N; Watanabe K; Suzuki Y; Nagamine T; +  
CORPORATE SOURCE: Department of Pathology, National Institute of Health,  
Tokyo, Japan.  
SOURCE: VACCINE, (1994 Sep) 12 (12) 1083-9.  
Journal code: 8406899. ISSN: 0264-410X.  
PUB. COUNTRY: ENGLAND: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199501  
ENTRY DATE: Entered STN: 19950126  
Last Updated on STN: 19950126  
Entered Medline: 19950119

L8 ANSWER 5 OF 28 MEDLINE on STN  
ACCESSION NUMBER: 94295246 MEDLINE  
DOCUMENT NUMBER: 94295246 PubMed ID: 8023550  
TITLE: Synergistic action of cholera toxin B subunit (and  
Escherichia coli heat-labile toxin B subunit) and a trace  
amount of cholera whole toxin as an adjuvant for nasal  
**influenza vaccine**.  
AUTHOR: Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K;  
Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H; +  
CORPORATE SOURCE: Department of Pathology, National Institute of Health,  
Tokyo, Japan.  
SOURCE: VACCINE, (1994 Apr) 12 (5) 419-26.  
Journal code: 8406899. ISSN: 0264-410X.  
PUB. COUNTRY: ENGLAND: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199408  
ENTRY DATE: Entered STN: 19940815  
Last Updated on STN: 19940815  
Entered Medline: 19940804

L8 ANSWER 6 OF 28 MEDLINE on STN  
ACCESSION NUMBER: 93372364 MEDLINE  
DOCUMENT NUMBER: 93372364 PubMed ID: 8364212  
TITLE: Neutrophils do not bind to or phagocytize human immune  
complexes formed with **influenza virus**.  
AUTHOR: Ratcliffe D R; Michl J; Cramer E B  
CORPORATE SOURCE: Department of Anatomy, State University of New York Health  
Science Center, Brooklyn 11203.  
CONTRACT NUMBER: AI-16480 (NIAID)  
SOURCE: BLOOD, (1993 Sep 1) 82 (5) 1639-46.  
Journal code: 7603509. ISSN: 0006-4971.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 199310  
ENTRY DATE: Entered STN: 19931022  
Last Updated on STN: 19931022  
Entered Medline: 19931005

L8 ANSWER 7 OF 28 MEDLINE on STN  
ACCESSION NUMBER: 88117435 MEDLINE  
DOCUMENT NUMBER: 88117435 PubMed ID: 2828525  
TITLE: Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine.  
AUTHOR: Lelie P N; Reesink H W; Lucas C J  
CORPORATE SOURCE: Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam.  
SOURCE: JOURNAL OF MEDICAL VIROLOGY, (1987 Nov) 23 (3) 297-301.  
Journal code: 7705876. ISSN: 0146-6615.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals; AIDS  
ENTRY MONTH: 198803  
ENTRY DATE: Entered STN: 19900308  
Last Updated on STN: 19900308  
Entered Medline: 19880315

L8 ANSWER 8 OF 28 MEDLINE on STN  
ACCESSION NUMBER: 86046496 MEDLINE  
DOCUMENT NUMBER: 86046496 PubMed ID: 3877382  
TITLE: Cell-mediated lysis of **heat-inactivated influenza virus**-coated murine targets.  
AUTHOR: Hosaka Y; Sasao F; Ohara R  
SOURCE: VACCINE, (1985 Sep) 3 (3 Suppl) 245-51.  
Journal code: 8406899. ISSN: 0264-410X.  
PUB. COUNTRY: ENGLAND: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 198512  
ENTRY DATE: Entered STN: 19900321  
Last Updated on STN: 19900321  
Entered Medline: 19851213

L8 ANSWER 9 OF 28 MEDLINE on STN  
ACCESSION NUMBER: 84060244 MEDLINE  
DOCUMENT NUMBER: 84060244 PubMed ID: 6605933  
TITLE: Persistence of **influenza** as an **immunogen** in pulmonary **antigen**-presenting cells.  
AUTHOR: Lipscomb M F; Yeakel-Houlihan D; Lyons C R; Gleason R R;  
Stein-Streilein J  
CONTRACT NUMBER: HL 23870 (NHLBI)  
SOURCE: INFECTION AND IMMUNITY, (1983 Dec) 42 (3) 965-72.  
Journal code: 0246127. ISSN: 0019-9567.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 198401  
ENTRY DATE: Entered STN: 19900319  
Last Updated on STN: 19970203  
Entered Medline: 19840107

L8 ANSWER 10 OF 28 MEDLINE on STN  
ACCESSION NUMBER: 76181590 MEDLINE  
DOCUMENT NUMBER: 76181590 PubMed ID: 4969  
TITLE: Experiments on the role of virus infections in the pathogenesis of bronchial asthma. The role of innate or acquired insufficiency or ergotropic adaptation in the mechanism of genesis of bronchial asthma.  
AUTHOR: Filipp G  
SOURCE: ALLERGOLOGIA ET IMMUNOPATHOLOGIA, (1976 Jan-Feb) 4 (1) 15-28.  
PUB. COUNTRY: Spain  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 197607  
ENTRY DATE: Entered STN: 19900313  
Last Updated on STN: 19980206  
Entered Medline: 19760706

L8 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 2000:287404 CAPLUS  
DOCUMENT NUMBER: 133:295055  
TITLE: Safety and **immunogenicity** of intranasally administered **inactivated** trivalent virosome-formulated **influenza** **vaccine** containing Escherichia coli **heat-labile** toxin as a mucosal adjuvant  
AUTHOR(S): Gluck, Reinhard; Mischler, Robert; Durrer, Peter; Furer, Emil; Lang, Alois B.; Herzog, Christian; Cryz, Stanley J., Jr.  
CORPORATE SOURCE: Swiss Serum and Vaccine Institute Berne, Bern, 3018, Switz.  
SOURCE: Journal of Infectious Diseases (2000), 181(3), 1129-1132  
PUBLISHER: CODEN: JIDIAQ; ISSN: 0022-1899  
DOCUMENT TYPE: University of Chicago Press  
LANGUAGE: Journal  
REFERENCE COUNT: English  
16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 1993:567717 CAPLUS  
DOCUMENT NUMBER: 119:167717  
TITLE: Hypericin treatment of vaccine agents for improved immunogenicity  
INVENTOR(S): Meruelo, Daniel; Lavie, Gad  
PATENT ASSIGNEE(S): New York University, USA  
SOURCE: PCT Int. Appl., 42 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 9314197	A1	19930722	WO 1993-US364	19930119
W: AU, CA, JP				

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE  
 AU 9334745 A1 19930803 AU 1993-34745 19930119  
 PRIORITY APPLN. INFO.: US 1992-821945 19920116  
 WO 1993-US364 19930119

L8 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 1986:107771 CAPLUS  
 DOCUMENT NUMBER: 104:107771  
 TITLE: Sensitive method for rapid detection of influenza A antibodies in human serum  
 INVENTOR(S): Wruck, Klaus  
 PATENT ASSIGNEE(S): Fed. Rep. Ger.  
 SOURCE: Ger. Offen., 11 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3426010	A1	19860116	DE 1984-3426010	19840714
PRIORITY APPLN. INFO.:			DE 1984-3426010	19840714

L8 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 1983:196233 CAPLUS  
 DOCUMENT NUMBER: 98:196233  
 TITLE: Effect of **influenza A virus** on leukocyte histamine release  
 AUTHOR(S): Busse, William W.; Swenson, Cheri A.; Borden, Ernest C.; Treuhaft, Mary W.; Dick, Elliot C.  
 CORPORATE SOURCE: Dep. Med. Hum. Oncol., Univ. Wisconsin, Madison, WI, USA  
 SOURCE: Journal of Allergy and Clinical Immunology (1983), 71(4), 382-8  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

L8 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 1962:406965 CAPLUS  
 DOCUMENT NUMBER: 57:6965  
 ORIGINAL REFERENCE NO.: 57:1448i,1449a-b  
 TITLE: Lowered resistance to **influenza** infection of mice following immunization with mercurial-inactivate **influenza virus**  
 AUTHOR(S): Ogasawara, K.; Aida, M.; Nagata, I.  
 CORPORATE SOURCE: Univ. Nagoya, Japan  
 SOURCE: Journal of Immunology (1961), 86, 599-605  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Unavailable

L8 ANSWER 16 OF 28 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
 ACCESSION NUMBER: 2001:2710 BIOSIS  
 DOCUMENT NUMBER: PREV200100002710  
 TITLE: Humoral and mucosal immune response in young healthy adults of an intranasal Escherichia coli **heat-labile toxin** (HLT) adjuvanted compared to a parenteral **inactivated virosome-formulated subunit influenza vaccine**.

AUTHOR(S) : Herzog, C. [Reprint author]; Durrer, P. [Reprint author]; Lang, A. [Reprint author]; Moser, R.; Spyr, C. [Reprint author]; Glueck, U.; Glueck, R. [Reprint author]  
CORPORATE SOURCE: Swiss Serum and Vaccine Inst. Berne, Berne, Switzerland  
SOURCE: Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, (2000) Vol. 40, pp. 251. print.  
Meeting Info.: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada. September 17-20, 2000. Interscience Conference on Antimicrobial Agents and Chemotherapy; American Society of Microbiology.  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
Conference; (Meeting Poster)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 21 Dec 2000  
Last Updated on STN: 21 Dec 2000

L8 ANSWER 17 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

ACCESSION NUMBER: 1998036607 EMBASE  
TITLE: Conference Science Medal 1997 lecture at British Pharmaceutical Conference, Scarborough, United Kingdom, September 15-18, 1997: Recent advances in vaccine adjuvants for systemic and mucosal administration.  
AUTHOR: O'Hagan D.T.  
CORPORATE SOURCE: D.T. O'Hagan, Chiron Corporation, 4560 Horton Street, Emeryville, CA 947608, United States  
SOURCE: Journal of Pharmacy and Pharmacology, (1998) 50/1 (1-10).  
Refs: 57  
ISSN: 0022-3573 CODEN: JPPMAB  
COUNTRY: United Kingdom  
DOCUMENT TYPE: Journal; Conference Article  
FILE SEGMENT: 026 Immunology, Serology and Transplantation  
029 Clinical Biochemistry  
030 Pharmacology  
037 Drug Literature Index  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L8 ANSWER 18 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

ACCESSION NUMBER: 96065969 EMBASE  
DOCUMENT NUMBER: 1996065969  
TITLE: Antibody responses in volunteers induced by nasal **influenza vaccine** combined with *Escherichia coli* heat labile enterotoxin B subunit containing a trace amount of the holotoxin.  
AUTHOR: Hashiguchi K.; Ogawa H.; Ishidate T.; Yamashita R.; Kamiya H.; Watanabe K.; Hattori N.; Sato T.; Suzuki Y.; Nagamine T.; Aizawa C.; Tamura S.-I.; Kurata T.; Oya A.  
CORPORATE SOURCE: E.N.T. Department, Kitasato Institute Hospital, 5-9-1 Shirokane, Minato-ku, Tokyo 108, Japan  
SOURCE: Vaccine, (1996) 14/2 (113-119).  
ISSN: 0264-410X CODEN: VACCDE  
COUNTRY: United Kingdom  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 004 Microbiology  
026 Immunology, Serology and Transplantation  
037 Drug Literature Index  
LANGUAGE: English

SUMMARY LANGUAGE: English

L8 ANSWER 19 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN  
ACCESSION NUMBER: 91203377 EMBASE  
DOCUMENT NUMBER: 1991203377  
TITLE: Nanoparticle-based drug delivery systems.  
AUTHOR: Kreuter J.  
CORPORATE SOURCE: Institut fur Pharmazeutische, Technologie, J.W.  
Goethe-Universitat, D-6000 Frankfurt, Germany  
SOURCE: Journal of Controlled Release, (1991) 16/1-2 (169-176).  
ISSN: 0168-3659 CODEN: JCREEC  
COUNTRY: Netherlands  
DOCUMENT TYPE: Journal; Conference Article  
FILE SEGMENT: 012 Ophthalmology  
026 Immunology, Serology and Transplantation  
027 Biophysics, Bioengineering and Medical  
Instrumentation  
047 Virology  
030 Pharmacology  
037 Drug Literature Index  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L8 ANSWER 20 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN  
ACCESSION NUMBER: 88120395 EMBASE  
DOCUMENT NUMBER: 1988120395  
TITLE: Application of the single radial complement fixation test  
for serodiagnosis of **influenza**, respiratory  
syncytial, mumps, adeno type 3, and herpes simplex type 1  
**virus** infections.  
AUTHOR: Sato S.; Ochiai H.; Niwayama S.  
CORPORATE SOURCE: Department of Virology, Toyama Medical and Pharmaceutical  
University, Toyama, Japan  
SOURCE: Journal of Medical Virology, (1988) 24/4 (395-404).  
ISSN: 0146-6615 CODEN: JMVIDB  
COUNTRY: United States  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 005 General Pathology and Pathological Anatomy  
026 Immunology, Serology and Transplantation  
047 Virology  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L8 ANSWER 21 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN  
ACCESSION NUMBER: 88056791 EMBASE  
DOCUMENT NUMBER: 1988056791  
TITLE: Recognition of noninfectious **influenza**  
**virus** by class I-restricted murine cytotoxic T  
lymphocytes.  
AUTHOR: Hosaka Y.; Sasao F.; Yamanaka K.; Bennink J.R.; Yewdell  
J.W.  
CORPORATE SOURCE: Department of Preventive Medicine, Research Institute for  
Microbial Diseases, Osaka University, Suita, Osaka 565,  
Japan  
SOURCE: Journal of Immunology, (1988) 140/2 (606- 610).  
ISSN: 0022-1767 CODEN: JOIMA3  
COUNTRY: United States  
DOCUMENT TYPE: Journal

FILE SEGMENT: 022 Human Genetics  
025 Hematology  
026 Immunology, Serology and Transplantation  
047 Virology  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L8 ANSWER 22 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

ACCESSION NUMBER: 83235382 EMBASE  
DOCUMENT NUMBER: 1983235382  
TITLE: Single radial complement fixation test using complement film. Assay of the antibody response to strain and type specific **antigens of influenza virus**.  
AUTHOR: Sato S.; Motoda S.; Iwase I.; Jo K.  
CORPORATE SOURCE: Denka Inst. Biol. Sci., Nihonbashi, Chuo-ku, Tokyo 103, Japan  
SOURCE: Journal of Virological Methods, (1983) 7/2 (57-64).  
CODEN: JVMEHD  
COUNTRY: Netherlands  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 047 Virology  
026 Immunology, Serology and Transplantation  
LANGUAGE: English

L8 ANSWER 23 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

ACCESSION NUMBER: 79093264 EMBASE  
DOCUMENT NUMBER: 1979093264  
TITLE: Single-radial-complement-fixation: A new immunodiffusion technique. 2. Assay of the antibody response to the internal **antigens** (MP and NP) of **influenza A virus** in human sera after vaccination and infection.  
AUTHOR: Haaheim R.  
CORPORATE SOURCE: Vaccine Dept., Nat. Inst. Publ. Hlth, Oslo 1, Norway  
SOURCE: Developments in Biological Standardization, (1977) VOL. 39/- (481-484).  
CODEN: DVBSA3  
COUNTRY: Switzerland  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 047 Virology  
LANGUAGE: English

L8 ANSWER 24 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

ACCESSION NUMBER: 78329744 EMBASE  
DOCUMENT NUMBER: 1978329744  
TITLE: Single-radial-complement-fixation: a new immunodiffusion technique.  
AUTHOR: Haaheim L.R.  
CORPORATE SOURCE: Vaccine Dept., Nat. Inst. Publ. Hlth, Postuttak-Oslo, Norway  
SOURCE: Bulletin of the World Health Organization, (1978) 56/1 (111-116).  
CODEN: BWHOA6  
COUNTRY: Switzerland  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 047 Virology  
017 Public Health, Social Medicine and Epidemiology

026 Immunology, Serology and Transplantation  
LANGUAGE: English  
SUMMARY LANGUAGE: French

L8 ANSWER 25 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

ACCESSION NUMBER: 77142518 EMBASE  
DOCUMENT NUMBER: 1977142518  
TITLE: Influence of vaccination with A/PR 8/34 (HO N1)  
**influenza virus** on the oncogenic activity  
of polyoma **virus** in newborn Wistar rats.  
AUTHOR: Desselberger U.; Drescher J.; Georgii A.; Ostertag H.  
CORPORATE SOURCE: Inst. Virol., Med. Hochsch., Hannover, Germany  
SOURCE: Cancer Research, (1976) 36/9 (I) (3047-3050).  
CODEN: CNREA8  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 037 Drug Literature Index  
016 Cancer  
LANGUAGE: English

L8 ANSWER 26 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

ACCESSION NUMBER: 74197797 EMBASE  
DOCUMENT NUMBER: 1974197797  
TITLE: Inactivation of A2/Hong Kong **influenza**  
**virus** by heat and by freeze thawing.  
Comparison of untreated and gamma irradiated preparations.  
AUTHOR: De Flora S.; Badolati G.  
CORPORATE SOURCE: Inst. Hyg., Univ. Genoa, Italy  
SOURCE: Bollettino dell'Istituto Sieroterapico Milanese, (1973)  
52/4 (293-305).  
CODEN: BISMAP  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 047 Virology  
LANGUAGE: English

L8 ANSWER 27 OF 28 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN

ACCESSION NUMBER: 1998:524076 SCISEARCH  
THE GENUINE ARTICLE: ZX643  
TITLE: Vaccination with glutaraldehyde-fixed bovine respiratory  
syncytial **virus** (BRSV)-infected cells stimulates  
a better immune response in lambs than vaccination with  
**heat-inactivated** cell-free BRSV  
AUTHOR: Keles I; Woldehiwet Z (Reprint); Murray R D  
CORPORATE SOURCE: UNIV LIVERPOOL, DEPT VET PATHOL, VET FIELD STN, WIRRAL L64  
7TE, MERSEYSIDE, ENGLAND (Reprint); UNIV LIVERPOOL, DEPT  
VET PATHOL, VET FIELD STN, WIRRAL L64 7TE, MERSEYSIDE,  
ENGLAND; UNIV LIVERPOOL, DEPT VET CLIN SCI & ANIM HUSB,  
VET FIELD STN, WIRRAL L64 7TE, MERSEYSIDE, ENGLAND  
COUNTRY OF AUTHOR: ENGLAND  
SOURCE: VACCINE, (JUL 1998) Vol. 16, No. 11-12, pp. 1172-1178.  
Publisher: ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE,  
KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND.  
ISSN: 0264-410X.  
DOCUMENT TYPE: Article; Journal  
FILE SEGMENT: LIFE; AGRI  
LANGUAGE: English  
REFERENCE COUNT: 32

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L8 ANSWER 28 OF 28 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN

ACCESSION NUMBER: 91:417619 SCISEARCH  
THE GENUINE ARTICLE: FX482  
TITLE: NANOPARTICLE-BASED DRUG DELIVERY SYSTEMS  
AUTHOR: KREUTER J (Reprint)  
CORPORATE SOURCE: JW GOETHE UNIV, INST PHARMAZEUT TECHNOL, W-6000 FRANKFURT,  
GERMANY (Reprint)  
COUNTRY OF AUTHOR: GERMANY  
SOURCE: JOURNAL OF CONTROLLED RELEASE, (1991) Vol. 16, No. 1-2,  
pp. 169-176.  
DOCUMENT TYPE: Article; Journal  
FILE SEGMENT: ENGI  
LANGUAGE: ENGLISH  
REFERENCE COUNT: No References Keyed  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

## WEST Search History

DATE: Tuesday, December 09, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
	<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR</i>		
L10	L9 and l5	42	L10
L9	influenza same inactivat\$7 and (tablet or oral)	415	L9
L8	denatur\$3 with antigen and vaccine same influenza	86	L8
L7	L6 and @py<2000	26	L7
L6	L5 and L3	111	L6
L5	L2 and (heat-inactivat\$5 or heat adj inactivat\$5 or denatur\$4) with (antigen or protein or HA or haemagglutinin or virus or influenza)	164	L5
L4	L3 and (multivalent or combination or polyvalent or bivalent) same influenza	49	L4
L3	L2 and (multivalent or combination or polyvalent or bivalent) same (vaccine or composition)	185	L3
L2	(heat adj inactivat\$5 or heat-inactivat\$5 or denature) same (virus or influenza or antigen\$5) and (influenza same virus) same (vaccine or antigen or immunogen\$6)	272	L2
L1	(heat adj inactivat\$5 or heat-inactivat\$5) same (influenza same virus and vaccine)	11	L1

END OF SEARCH HISTORY

## WEST Search History

DATE: Tuesday, December 09, 2003

### Set Name Query

side by side

*DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR*

		<u>Hit Count</u>	<u>Set Name</u>
		result set	
L3	L2 and oral.clm.	22	L3
L2	L1 and influenza.clm.	116	L2
L1	(vaccine or immunogen\$5) same (oral) and (pill or tablet or capsule) and influenza adj virus	567	L1

END OF SEARCH HISTORY



National  
Library  
of Medicine

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	PMC	Journals	E
Search PubMed	<input type="text"/> for							
			<input checked="" type="checkbox"/> Limits	PreviewIndex	History	Catalog	Details	

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.


Entrez PubMed

PubMed Services

Related Resources

Search	Most Recent Queries	Time	Result
#17	<b>Search (#1 or #12) AND influenza AND inactivat*</b> Field: Title/Abstract, Limits: Publication Date to 2000/08/24	14:19:10	35
#18	<b>Search #17 AND (pill or tablet or capsule)</b> Field: Title/Abstract, Limits: Publication Date to 2000/08/24	14:19:06	0
#12	<b>Related Articles for PubMed (Select 6480615)</b>	14:17:30	229
#1	<b>Search oral AND vaccine AND influenza</b> Field: Title/Abstract, Limits: Publication Date to 2000/08/24	14:11:39	117
#9	<b>Search oral AND vaccine AND influenza AND (pill or tablet)</b> Field: Title/Abstract, Limits: Publication Date to 2000/08/24	14:10:19	1

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)  
[Freedom of Information Act](#) | [Disclaimer](#)



Entrez PubMed

Nucleotide

Protein

Genome

Structure

PMC

Journals

Be

Search PubMed

for

Preview

Go

Clear

 Limits

Preview/Index

History

Clipboard

Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

Search	Most Recent Queries	Time	Result
#33 Search #32 not #11 Field: Title/Abstract, Limits: Publication Date to 2000/08/24		09:46:02	8
#32 Search heat-inactivat* AND virus AND influenza Field: Title/Abstract, Limits: Publication Date to 2000/08/24		09:38:13	36
#31 Search heat-inactivat* AND virus Field: Title/Abstract, Limits: Publication Date to 2000/08/24		09:38:01	409
#28 Search heat-inactivat* AND vaccine AND virus Field: Title/Abstract, Limits: Publication Date to 2000/08/24		09:37:03	33
#27 Search heat-inactivat* AND vaccine Field: Title/Abstract, Limits: Publication Date to 2000/08/24		09:35:55	106
#24 Search heat inactivat* AND influenza AND antigen Field: Title/Abstract, Limits: Publication Date to 2000/08/24		09:34:45	4
#23 Search heat inactivat* AND influenza AND vaccine Field: Title/Abstract, Limits: Publication Date to 2000/08/24		09:34:39	2
#22 Search heat-inactivat* AND influenza AND vaccine Field: Title/Abstract, Limits: Publication Date to 2000/08/24		09:34:32	2
#21 Search heat-inactivated AND influenza AND vaccine Field: Title/Abstract, Limits: Publication Date to 2000/08/24		09:34:25	1
#20 Search influenza AND heat-inactivated AND vaccine Field: Title/Abstract, Limits: Publication Date to 2000/08/24		09:33:44	1
#17 Search influenza AND heat-inactivated AND (oral or mucosal or mucus) Field: Title/Abstract, Limits: Publication Date to 2000/08/24		09:32:08	0
#16 Search influenza AND heat-inactivated AND (oral or muc*) Field: Title/Abstract, Limits: Publication Date to 2000/08/24		09:31:44	1
#11 Search influenza AND heat-inactivated Field: Title/Abstract, Limits: Publication Date to 2000/08/24		09:27:36	28

#3 Search **influenza AND vaccine AND heat inactivated** 09:22:06 12  
Field: **Title/Abstract**, Limits: **Publication Date to 2000/08/24**

#2 Search **influenza AND vaccine AND inactivated** Field: 09:21:56 644  
Title/Abstract, Limits: **Publication Date to 2000/08/24**

#1 Search **influenza AND vaccine AND inactivated** 09:21:26 1174

[Clear History](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

Dec 1 2003 07:03:59